CareLit · DOI-Nachweis · Pneumologie
Risk of not receiving 2nd line therapy is high in EGFR mt+ patients: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients
DOI 10.1055/s-0039-1678025
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ Roeper, M Falk, S Schatz, M Tiemann, S Sackmann, D Ukena, C Wesseler, G Wiest, L Heukamp, F Griesinger
ZeitschriftPneumologie
AusgabeS 01 S 01/2019
Jahrgang / SeitenJg. 73
Kernaussage aus der Literatur
Abstract-Vorschau
Risk of not receiving 2nd line therapy is high in EGFR mt+ patients: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients
Zitieren
Zitierempfehlung
J Roeper, M Falk, S Schatz, M Tiemann, S Sackmann, D Ukena, C Wesseler, G Wiest, L Heukamp, F Griesinger (2019) Risk of not receiving 2nd line therapy is high in EGFR mt+ patients: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients. Pneumologie, 73 (S 01 S 01). https://doi.org/10.1055/s-0039-1678025
Mit CareLit weiterarbeiten